icon-folder.gif   Conference Reports for NATAP  
  65th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 7-11 2014
Back grey_arrow_rt.gif
All-Oral Fixed-Dose Combination Therapy With Daclatasvir/Asunaprevir/Beclabuvir, ±Ribavirin, for Patients With Chronic HCV Genotype 1 Infection and Compensated Cirrhosis: UNITY-2 Phase 3 SVR12 Results
  Reported by Jules Levin
AASLD 2014 Boston Nov 7-11
Muir AJ,1 Poordad F,2 Lalezari J,3 Everson GJ,4 Dore GJ,5 Kwo P,6 Hezode C,7 Pockros PJ,8 Tran A,9 Ramji A,10 Yang R,11 Hughes EA,11 Swenson ES,12 Yin PD12 on behalf of the UNITY-2 Study Team
1Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; 2Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX; 3Quest Clinical Research, San Francisco, CA; 4University of Colorado School of Medicine, Denver, CO; 5Kirby Institute, UNSW Australia, Sydney, NSW, Australia; 6Indiana University School of Medicine, Indianapolis, IN; 7Hopital Henri Mondor, Universite Paris-Est, Creteil, France; 8Scripps Clinic, La Jolla, CA; 9Centre Hospitalier Universitaire de Nice, Nice, France; 10University of British Columbia, Vancouver, BC, Canada; 11Bristol-Myers Squibb, Princeton, NJ; 12Bristol-Myers Squibb, Wallingford, CT.